PMID- 17645781
OWN - NLM
STAT- MEDLINE
DCOM- 20071017
LR  - 20070813
IS  - 1347-9032 (Print)
IS  - 1347-9032 (Linking)
VI  - 98
IP  - 9
DP  - 2007 Sep
TI  - HLA class I antigen expression is associated with a favorable prognosis in early 
      stage non-small cell lung cancer.
PG  - 1424-30
AB  - Human leukocyte antigen (HLA) class I displays a repertoire of endogenously 
      processed peptides to CD8(+) T lymphocytes. The present study assessed 
      correlations between HLA class I expression, clinicopathologic factors, and 
      tumor-infiltrating immune cells in human non-small cell lung cancers (NSCLC). 
      Expression of HLA class I was assessed in 161 resected primary NSCLC by 
      immunohistochemistry using EMR8-5, a novel monoclonal anti-pan HLA class I heavy 
      chain antibody. Expression of HLA class I was classified into three categories: 
      strongly positive, weakly positive, or negative. Tumor-infiltrating CD8(+) 
      lymphocytes and CD56(+) natural killer cells within cancer nests and stroma were 
      also counted. Expression of HLA class I was strongly positive in 50 tumors, 
      weakly positive in 57 tumors, and negative in 54 tumors. Down-regulation of HLA 
      class I was significantly correlated with male sex, history of smoking, 
      non-adenocarcinoma histology, and moderate-/low-grade differentiation. The 
      density of cancer nest-infiltrating CD8(+) cells in HLA class I-negative tumors 
      was significantly decreased compared to that in HLA class I strongly positive 
      tumors (P < 0.01). Kaplan-Meier analysis revealed a significant favorable 
      influence on overall survival for patients displaying tumors with strongly 
      positive expression of HLA class I (P < 0.01). Multivariate analysis revealed 
      down-regulation of HLA class I as an independent factor of poor prognosis in 
      pathological stage I patients, but not in late-stage patients. These results 
      suggest that down-regulation of HLA class I expression in NSCLC is a marker of 
      poor prognosis, and this may play a critical role in immune surveillance of 
      patients with NSCLC.
FAU - Kikuchi, Eiki
AU  - Kikuchi E
AD  - First Department of Medicine, Hokkaido University School of Medicine, North 15, 
      West 7, Kitaku, Sapporo 060-8638, Japan.
FAU - Yamazaki, Koichi
AU  - Yamazaki K
FAU - Torigoe, Toshihiko
AU  - Torigoe T
FAU - Cho, Yasushi
AU  - Cho Y
FAU - Miyamoto, Masaki
AU  - Miyamoto M
FAU - Oizumi, Satoshi
AU  - Oizumi S
FAU - Hommura, Fumihiro
AU  - Hommura F
FAU - Dosaka-Akita, Hirotoshi
AU  - Dosaka-Akita H
FAU - Nishimura, Masaharu
AU  - Nishimura M
LA  - eng
PT  - Journal Article
DEP - 20070723
PL  - England
TA  - Cancer Sci
JT  - Cancer science
JID - 101168776
RN  - 0 (HLA Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (beta 2-Microglobulin)
SB  - IM
MH  - Aged
MH  - Carcinoma, Non-Small-Cell Lung/*immunology/mortality/pathology
MH  - Female
MH  - Gene Expression Regulation, Neoplastic/*immunology
MH  - HLA Antigens/*biosynthesis/*genetics/immunology
MH  - Histocompatibility Antigens Class I/*biosynthesis/*genetics/immunology
MH  - Humans
MH  - Lung Neoplasms/*immunology/mortality/pathology
MH  - Lymphocytes, Tumor-Infiltrating/immunology/pathology
MH  - Male
MH  - Prognosis
MH  - Retrospective Studies
MH  - beta 2-Microglobulin/biosynthesis/genetics
EDAT- 2007/07/25 09:00
MHDA- 2007/10/18 09:00
CRDT- 2007/07/25 09:00
PHST- 2007/07/25 09:00 [pubmed]
PHST- 2007/10/18 09:00 [medline]
PHST- 2007/07/25 09:00 [entrez]
AID - CAS558 [pii]
AID - 10.1111/j.1349-7006.2007.00558.x [doi]
PST - ppublish
SO  - Cancer Sci. 2007 Sep;98(9):1424-30. doi: 10.1111/j.1349-7006.2007.00558.x. Epub 
      2007 Jul 23.